- ¥136bn
- ¥128bn
- ¥19bn
Brief: Peptidream Inc. - Initiation Of Phase 1 Clinical Trial By Novartis Marks Milestone For Peptidream
Brief: PeptiDream Announces First Dosing Of 64cu-Pd-29,875 In Gastric Cancer Patients
Table: Peptidream -Q1 group results (IFRS)
Brief: Peptidream Announces The Initiation Of Phase 1 Clinical Trial By Its Collaboration Partner
Table: Peptidream -2025 parent results
Table: Peptidream -2025 group results (IFRS)
Brief: Peptidream And Alnylam Announce Achievement Of Key Milestone In Sirna Conjugate Discovery Collaboration
Brief: Peptidream Announces Pre-Clinical Results Of Oral Il-17A And Il-17F Inhibitor
Table: Peptidream -2025 group forecast(IFRS)
Table: Peptidream -9-MTH group results (IFRS)
Table: Peptidream 6-MTH group results (IFRS)
Table: Peptidream -Q1 group results (IFRS)
Table: Peptidream -2024 parent results
Table: Peptidream -2024 group results (IFRS)
Brief: Peptidream Inc- To Spend About 10 Billion Yen To Build New Manufacturing Facility In Chiba, Japan
Brief: Peptidream Announces Preclinical Results Demonstrating Efficacy Of Oral Myostatin Inhibitors In Preventing Loss Of Lean Mass Associated With Semaglutide Treatment
Table: Peptidream -9-MTH group results (IFRS)
Brief: NCC, PeptiDream Announce First Dosing of 64Cu-PD-32766 In Patient with Clear Cell Renal Cell Carcinoma
Table: Peptidream -Q1 group results (IFRS)